• Improving Patient 
    Outcomes in
    Solid Tumor
    Cancer Treatment

    BIO300
    A New Class of Cancer Drug

  •  

    COVID-19

     

    BIO300
    Preventing long term lung damage caused by inflammation

  • Keeping America Safe

    BIO300
    Protecting Civilians, First Responders and Our Military
    from Nuclear Accidents and Terrorism

Humanetics News

10.20.2020

Humanetics Corporation Presents New Data at the Radiation Research Society Meeting
Read More

10.08.20

Humanetics Board Member Vice Admiral Matthew L. Nathan, M.D. Talks with KTTV TV in Los Angeles about COVID-19's Lingering Effects and BIO 300's Clinical Trial
Watch the Interview

10.08.20

MassLive.com Interviews Humanetics Board Member Vice Admiral Matthew L. Nathan, M.D. about BIO 300 and Linking Radiation to Coronavirus in Effort to Help "Long Haulers"
Read the Article

10.06.20

Spectrum News 14 Speaks to Humanetics Board Member Vice Admiral Matthew L. Nathan, M.D. about BIO 300
Watch the Interview

10.01.20

Humanetics Board Member Vice Admiral Matthew L. Nathan, M.D. discusses BIO 300 and Treating COVID "Long Haulers" with WRAZ TV
Watch the Interview

09.29.20

Humanetics CEO Ron Zenk Talks to the Sun Current about BIO 300's Post-COVID-19 Lung Trial
Read More

09.15.20

Matthew L. Nathan, M.D., Former Surgeon General of the U.S. Navy, Joins Board of Directors
Read More

07.23.20

Humanetics CEO Ron Zenk Previews Upcoming BIO 300 COVID-19 Clinical Trial with WCCO TV
Watch the Interview

07.23.20

Humanetics Corporation Receives Funding from NIAID to Test BIO 300 in COVID-19 Patients
Read More

05.28.20

Humanetics Corporation Invited for Oral Presentation at Annual Meeting of American Society of Radiation Oncologists
Read More

02.19.20

Humanetics Acquires Manufacturing Assets for Radioprotectant Drug
Read More

05.06.20

Dr. Colin Chinn, Former Staff Surgeon, Joins Medical Advisory Board
Read More

10.01.19

Humanetics Received New $6 Million Contract from Department of Defense
Read More

10.23.18

Humanetics Corporation to Present at Annual Meeting of Society for Radiation Oncology
Read More

10.8.18

Humanetics Corporation Invited to Present Data on BIO 300 at Government Conference
Read More

09.25.18

Humanetics Corporation Presents Data on BIO 300 at Radiation Research Society Annual Meeting
Read More

07.17.18

Humanetics Corporation Awarded Patent for Oral Drug to Protect Warfighters and First Responders from Radiation Injury
Read More

04.12.18

Humanetics Corporation Awarded Federal Contract to Develop New Radiation Countermeasure to Protect the Lungs
Read More

02.12.18

Humanetics Corporation Presents at 2018 BIO CEO and Investor Conference
Read More

01.30.18

Humanetics Corporation Presents Data on Drug to Protect Cardiac Cells Against Toxicity From Space-Like Radiation

Read More

01.11.18

Vice Admiral Matthew L. Nathan, M.D., Former Surgeon General of the U.S. Navy, Joins Humanetics' Medical Advisory Board

Read More

10.10.17

Humanetics Receives New Grant from NASA

Read More

10.31.17

Humanetics Presents Data for Cancer Drug

Read More

09.26.17

Humanetics Receives $3.8 Million Grant from Department of Defense

Read More

09.12.17

Humanetics Receives Patent for Cancer Drug

Read more

08.22.17

Humanetics to Present at Department of Defense Scientific Meeting

Read more